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Introduction {#sec1}
============

Understanding the molecular mechanisms governing transplantation acceptance is essential for successful stem cell-based therapies. Undifferentiated embryonic stem cells (ESCs) have been considered "immune privileged" tissues, but they become much more immunogenic upon in vivo differentiation ([@bib29], [@bib42]). The low immunogenicity of undifferentiated ESCs has been associated with the low level of major histocompatibility complex (MHC) molecules and the absence of co-stimulatory molecules that would promote activation of allo-specific T cells ([@bib1], [@bib4], [@bib5]). However, mechanisms underlying the lack of immunogenicity seem to be more complicated than originally speculated. Koch et al. have demonstrated that ESCs exert local immunosuppression through the production of soluble anti-inflammatory cytokines ([@bib14]). We also observed that undifferentiated ESC-derived soluble factors (i.e., the water-soluble fraction of sonicated ESCs) modulate T cell functions ([@bib25]). However, the defined molecules and underlying mechanisms of their actions have not been revealed.

Here, we report that milk fat globule epidermal growth factor 8 (MFG-E8)/lactadherin is a key determinant. MFG-E8, a secreted glycoprotein, was initially identified in mammary gland epithelial cells. Further studies have revealed its anti-inflammatory functions in macrophages, where it assists in the phagocytosis of apoptotic cells through α~V~β~3~/α~V~β~5~ integrins ([@bib2], [@bib12], [@bib41]). However, molecular mechanisms pertinent to MFG-E8 expression in health and diseased conditions remain largely unknown. In addition, the functions of MFG-E8 on T cells and ESCs have not yet been reported. In this study, we demonstrate that MFG-E8 is essential in sustaining the "immune privileged" status of undifferentiated ESCs and in facilitating the acceptance of ESC-derived tissues across allogeneic MHC barriers and thus enabling the suppression of T cell-mediated immune responses through the PKCθ pathway.

Results {#sec2}
=======

Undifferentiated, but Not Differentiated, ESCs Express High Levels of MFG-E8, and Upregulation of MFG-E8 Enables Survival and Engraftment of Undifferentiated and Differentiated Allogeneic ESCs {#sec2.1}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To define molecules with immunomodulatory potential in ESCs, we searched literature and proteomics databases ([@bib8], [@bib30], [@bib31], [@bib37]) and selected the proteins that were closely associated with immune regulation and also highly expressed in and secreted by undifferentiated ESCs while diminished upon ESC differentiation. We found that, except for MFG-E8, other proteins originally selected were inefficient in the inhibition of T cell function in preliminary experiments and so were excluded from further investigation. As shown in [Figures 1](#fig1){ref-type="fig"}A and [2](#fig2){ref-type="fig"}A, the gene and protein expression of MFG-E8 was diminished in a timely manner after spontaneous in vitro differentiation of embryoid body (EB) (i.e., formation of cellular aggregates). In addition, *Mfg-e8* gene was also downregulated after in vivo ESC differentiation (i.e., teratoma formation; [Figure 1](#fig1){ref-type="fig"}B). To determine whether MFG-E8 has an immunoregulatory function in ESCs, we transduced *Mfg-e8* gene into B6 wild-type ESCs (B6-WT, derived from C57BL/6 H-2^b^ mice) with a lentiviral vector (B6-MFG-E8 ESCs; [Figure 2](#fig2){ref-type="fig"}A) and implanted B6 B6-WT and B6-MFG-E8 ESCs into syngeneic C57BL/6 recipients. As expected, both B6-WT and B6-MFG-E8 ESCs formed teratomas containing significantly different levels of MFG-E8 proteins in the recipients ([Figure 2](#fig2){ref-type="fig"}B). In both instances, teratomas displayed the same differentiated structures representing three germ layers and showed a similar level of the MHC class I determinant H-2K^b^ expression 4 weeks after injections ([Figures 2](#fig2){ref-type="fig"}C, 2D, and [3](#fig3){ref-type="fig"}B). In addition, differentiated B6-WT ESCs showed a significant decrease in gene and protein expression of MFG-E8 in comparison to their undifferentiated counterparts. In contrast, teratomas generated from B6-MFG-E8 ESCs sustained a high level of MFG-E8 expression ([Figures 1](#fig1){ref-type="fig"}B and [2](#fig2){ref-type="fig"}B). These results suggest that the differentiation capacity and MHC-I expression in B6 ESCs are not altered after MFG-E8 overexpression.

To determine whether MFG-E8 in ESCs was capable of facilitating graft acceptance across an MHC barrier, we subcutaneously transplanted B6-MFG-E8 ESCs into allogeneic BALB/c (H-2^d^) mice. In allogeneic settings, B6-WT ESCs failed to form any detectable teratomas, whereas B6-MFG-E8 ESCs survived and generated five teratomas in nine implantations ([Figure 1](#fig1){ref-type="fig"}C). Immunofluorescent staining and histological analysis demonstrated that allogeneic B6-WT ESCs elicited severe graft infiltration of CD4^+^ and CD8^+^ T cells in the transplanted remnant ([Figures 1](#fig1){ref-type="fig"}D and 1E), suggesting that allogeneic B6-WT ESCs and their derivatives were destroyed by host alloimmune responses. Conversely, allogeneic B6-MFG-E8 ESCs formed typical teratomas with unnoticeable tissue necrosis but detectable MHC-I (H-2K^b^) expression ([Figure 1](#fig1){ref-type="fig"}D). Importantly, in contrast to B6-WT controls, B6-MFG-E8 teratomas displayed limited numbers of infiltrating T cells while containing a high percentage of CD4^+^Foxp3^+^ regulatory T cells (Tregs; [Figure 1](#fig1){ref-type="fig"}F). Semiquantitative immunohistological analyses of syngeneic and allogeneic teratomas are summarized in [Table S1](#mmc1){ref-type="supplementary-material"}.

To further determine whether MFG-E8 also facilitates engraftment of in vitro differentiated allogeneic ESCs, we derived EBs from B6-WT and B6-MFG-E8 ESCs by formation of cellular aggregates and cultured them in the absence of leukemia inhibitory factor for 7 days. This differentiation procedure has been used commonly in the field and represents a turning point for the early development of specialized tissues ([@bib16], [@bib23], [@bib26], [@bib38]). The differentiated EBs showed low levels of pluripotency genes ([Figure 3](#fig3){ref-type="fig"}E) but increased levels of MHC-I (H-2K^b^) prior to transplantation under the kidney capsule of syngeneic or allogeneic recipients ([Figure 3](#fig3){ref-type="fig"}A). As expected, all implanted EBs were accepted by syngeneic mice and grew well ([Figures 3](#fig3){ref-type="fig"}F and 3G). However, in allogeneic BALB/c recipients, the majority of B6-WT EBs failed to grow and the implants showed severe infiltration of T cells with a low proportion of CD4^+^Foxp3^+^ Tregs. In contrast, eight of nine allogeneic mice transplanted with B6-MFG-E8 EBs were engrafted, and the implants showed limited T cell infiltration with a higher proportion of CD4^+^Foxp3^+^ Tregs ([Figures 1](#fig1){ref-type="fig"}G, 1H, and [S1](#mmc1){ref-type="supplementary-material"}).

It is evident that overexpression of MFG-E8 in both undifferentiated and differentiated ESCs is sufficient to reduce allogeneic rejection ([Figure 1](#fig1){ref-type="fig"}), despite a significant increase in the expression of MHC-I ([Figures 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}) and co-stimulatory molecules that made differentiated ESCs more immunogenic ([@bib6]). Since overexpression of MFG-E8 does not inhibit MHC-I and II expression ([Figure 1](#fig1){ref-type="fig"} and [Figure 3](#fig3){ref-type="fig"}), the immunoregulation of MFG-E8 is not through blocking MHC. Given that sustained MFG-E8 levels in the grafts were inversely associated with the presence of T cell infiltration ([Figure 1](#fig1){ref-type="fig"}; [Table S1](#mmc1){ref-type="supplementary-material"}), MFG-E8 might contribute to graft acceptance by suppressing T cell responses. Although involvements of other innate inflammatory cells cannot be fully excluded, a study by Swijnenburg et al. has suggested that innate responses can be initiated by surgical procedures and are not completely specific to ESC implants ([@bib34]). Accordingly, we focused on the direct role of MFG-E8 in T cell regulation, a question that has not been addressed.

MFG-E8 in ESCs Suppresses T Cell Activation and Proliferation {#sec2.2}
-------------------------------------------------------------

Based on the above in vivo observations and previous findings that ESC-derived soluble factors inhibited T cell activation ([@bib25]), we wanted to make a direct link between ESC-produced MFG-E8 and T cell activation and proliferation. ESC-derived soluble factors suppressed expression of activation markers (CD25, CD69, and CD44) in both CD4^+^ and CD8^+^ effector T cells stimulated in vitro, and neutralization of MFG-E8 with a specific antibody markedly mitigated the suppressive effects of ESC-derived soluble factors ([Figures 4](#fig4){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A), suggesting that MFG-E8 is responsible for ESC-mediated T cell inhibition.

To further assess the immunomodulatory functions of MFG-E8 on T cells, we stimulated the cultured mouse splenic T cells in the absence or presence of recombinant mouse MFG-E8 (rmMFG-E8). Treatment with rmMFG-E8 significantly suppressed both CD4^+^ and CD8^+^ effector T cell activation, resulting in a 2-fold decrease in CD25, CD44, and CD69 expression ([Figure 4](#fig4){ref-type="fig"}B). Conversely, introduction of MFG-E8 blocking antibody, but not an isotype control antibody, abrogated the suppression of activation ([Figure 4](#fig4){ref-type="fig"}B). Moreover, CD4^+^ and CD8^+^ T cell activation was not affected after treatment with soluble factors derived from differentiated ESCs expressing low level of MFG-E8, with the majority of T cells showing upregulated activation markers after anti-CD3/CD28 stimulation. In contrast, reconstitution of differentiated ESC-derived soluble factors with rmMFG-E8 restored suppression, as indicated by a reduction of all three activation markers in T cells ([Figure 4](#fig4){ref-type="fig"}B). These results demonstrate that MFG-E8 is indeed a key component in ESC-mediated T cell inactivation.

We further tested whether MFG-E8 was capable of suppressing T cell proliferation using a carboxyfluorescein succinimidyl ester (CFSE) dilution assay with CFSE-labeled CD3^+^ T cells. In the presence of rmMFG-E8, reduced cell divisions in activated T cells were observed, similar to those treated with undifferentiated ESC-derived soluble factors ([Figure 4](#fig4){ref-type="fig"}C). Conversely, differentiated ESC-derived soluble factors did not inhibit T cell proliferation, whereas MFG-E8 supplementation almost fully restored the suppressive effect on T cell proliferation ([Figure 4](#fig4){ref-type="fig"}C).

Together, the aforementioned results demonstrate that MFG-E8 is a key component in ESC-derived soluble factors that suppresses T cell activation and proliferation, providing the evidence that MFG-E8 produced by undifferentiated ESCs is directly involved in repressing T cell immune responses in addition to its conventional role in facilitating phagocytosis of apoptotic cells. Consequently, loss of MFG-E8 expression following ESC differentiation restores normal T cell responses to reject allogeneic implants; conversely, sustained MFG-E8 expression in differentiated cells inhibits T cell proliferation and activation, promoting graft acceptance ([Figures 1](#fig1){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

Since cells deficient in MHC-I expression (e.g., ESCs) could be recognized by natural killer (NK) cells, we examined whether MFG-E8 also suppresses NK cell function as measured by interferon-γ (IFN-γ) production ([@bib7]). As shown in Figure S2B, IFNγ production in fractionated NK cells was inhibited after treatment of the cells with ESC-derived soluble factors or rmMFG-E8. It is possible that NK cells participate in the early recognition of transplanted ESCs that express low MHC-I based on "missing-self" theory ([@bib32]). Because differentiated B6-MFG-E8 EBs expressing MHC-I (H-2K^b^) prior to transplantation are engrafted ([Figure 3](#fig3){ref-type="fig"}), it appears that T cells play a major role in successful engraftment, with the possible contribution of NK cells, warranting further investigation.

MFG-E8 in ESCs Suppresses Th1, Th2, and Th17 Subpopulations while Increasing Regulatory T Cells {#sec2.3}
-----------------------------------------------------------------------------------------------

Our results showed that B6-MFG-E8, but not B6-WT, implants displayed limited T cell infiltration with a high percentage of CD4^+^Foxp3^+^ Tregs ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). We therefore tested whether MFG-E8 in undifferentiated ESCs modulates T cell polarization induced by stimulation with anti-CD3/CD28 or phorbol myristate acetate (PMA). qPCR results examining the expression of lineage-specific transcription factors indicated a significant decrease in expression of transcriptional factors *Gata3* (Th2) and *Rorγt* (Th17) in T cells after treatments with rmMFG-E8 or undifferentiated ESC-derived soluble factors. Conversely, MFG-E8 neutralization restored *Gata3* and *Rorγt* expression ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, *T-bet* (Th1) gene expression was unaffected in all treatment conditions ([Figure 5](#fig5){ref-type="fig"}A) despite a marked decrease in gene expression of the Th1-specific cytokine *Ifnγ* ([Figure S3](#mmc1){ref-type="supplementary-material"}). In an attempt to further assess the changes in function of each T effector cell subset attributed to MFG-E8, T cells were intracellularly stained with IFN-γ (Th1), IL-4 (Th2), and IL-17 (Th17) antibodies. Consistent with changes in *Ifnγ* gene expression ([Figure S3](#mmc1){ref-type="supplementary-material"}), T cells treated with rmMFG-E8 exhibited a notable decrease in IFN-γ-producing effector cells ([Figure 5](#fig5){ref-type="fig"}B). Likewise, in accordance with downregulated *Gata3* and *Rorγt* gene expression, the numbers of IL-4- and IL-17-producing T cells were significantly decreased ([Figures 5](#fig5){ref-type="fig"}C and 5D). Neutralization of MFG-E8 effectively ameliorated the suppressive effects of rmMFG-E8 or ESC-derived soluble factors, restoring the numbers of IFN-γ-, IL-4-, and IL-17-producing T cells ([Figures 5](#fig5){ref-type="fig"}B--5D). These data suggest that ESC-produced MFG-E8 inhibits the development of Th1, Th2, and Th17 subpopulations.

Furthermore, consistent with upregulated *Foxp3* and *Tgfβ* gene expression (genes associated with regulatory T cells; [Figures 5](#fig5){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}) and increased proportions of CD4^+^Foxp3^+^ Tregs in the allografts after transplantation of B6-MFG-E8 ESCs and EBs ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}B), the CD4^+^CD25^+^Foxp3^+^ Treg subpopulation was markedly increased after treatment with rmMFG-E8 ([Figure 5](#fig5){ref-type="fig"}E). Of note, the elevated Treg subpopulation induced by ESC-derived soluble factors was almost completely blocked following the neutralization of MFG-E8 with an antibody ([Figure 5](#fig5){ref-type="fig"}E).

Collectively, our results provide direct evidence that ESC-produced MFG-E8 enhances polarization of the Treg subpopulation, suppresses Th1 function, and prevents the development of Th2 and Th17 T cells. Previous studies have shown that increased Treg infiltration in tumor tissues was associated with elevated macrophage MFG-E8 expression ([@bib13]) and development of autoimmunity was correlated with downregulated MFG-E8 levels ([@bib28], [@bib40]). Our study provides a direct link between MFG-E8 and Th1, Th2, Th17, and Treg T cells, demonstrating that undifferentiated ESCs are capable of skewing immune response toward an anti-inflammatory or immune tolerant status via MFG-E8.

MFG-E8 in Undifferentiated ESCs Suppresses T Cell Activation via Inhibition of PKCθ Phosphorylation {#sec2.4}
---------------------------------------------------------------------------------------------------

Given an indispensable role of PKCθ in T cell responses ([@bib9]) and our previous observation that ESC-derived soluble factors inhibit PKCθ phosphorylation ([@bib25]), we speculated that MFG-E8 might modulate T cells through PKCθ. Indeed, both undifferentiated ESC-derived soluble factors and rmMFG-E8 significantly suppressed PKCθ phosphorylation of activated T cells, and anti-MFG-E8 antibody abrogated the inhibitory effects ([Figures 6](#fig6){ref-type="fig"}A and 6B). Additionally, differentiated ESC- or myoblast C2C12-derived soluble factors containing little MFG-E8 did not significantly affect PKCθ phosphorylation in T cells. Conversely, supplement of differentiated ESC-derived soluble factors with rmMFG-E8 restored inhibition ([Figure 6](#fig6){ref-type="fig"}C).

It is known that T cells selectively upregulate integrin α~V~β~3~/α~V~β~5~ on their surface when encountering a specific PKCθ activator, PMA ([@bib10], [@bib17], [@bib27]). We reasoned that engagement of MFG-E8 to its integrin receptor on activated T cells might transduce a signal via PKCθ in ESC-mediated immunomodulation to control the level of T cell responses. As anticipated, western blot revealed that a blockade of α~V~β~3~/α~V~β receptor activity with an anti-CD51 (anti-α~V~) antibody alleviated the inhibitory effect of ESC-derived soluble factors or rmMFG-E8 on PKCθ phosphorylation ([Figure 6](#fig6){ref-type="fig"}D).

Additionally, to further confirm that inhibition of PKCθ would suppress T cell function, we transfected purified splenic T cells with scrambled RNA or PKCθ small interfering RNA (siRNA) prior to stimulation with antiCD3/CD28 ([Figure S4](#mmc1){ref-type="supplementary-material"}A). With PKCθ knockdown, T cell activation was impaired with a robust decrease in CD25^+^/CD69^+^ T cells in both CD4 and CD8 subpopulations ([Figure S4](#mmc1){ref-type="supplementary-material"}B).

Furthermore, MFG-E8 specifically abolished PMA-induced PKCθ activation ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Since PMA is a well-known molecule capable of upregulating PKCθ activity, but not PKC-α, β, δ, ε, and δ82 ([@bib11], [@bib35], [@bib36]), PKCθ is a key player involved in MFG-E8-mediated T cell regulation. A role for PKCθ in mouse cardiac rejection has been reported. PKCθ knockout mice exhibit an impaired alloimmune response and are susceptible to tolerance induction. While a subtherapeutic dose of anti-CD154 antibody or CTLA4-Ig failed to delay cardiac allograft rejection in wild-type mice, it could prevent cardiac allograft rejection in PKCθ knockout mice ([@bib19], [@bib39]). In this report, we made a connection between MFG-E8, PKCθ, and immune acceptance of differentiated ESC implants.

Discussion {#sec3}
==========

Molecules and mechanisms pertinent to the low immunogenicity of undifferentiated ESCs remain poorly understood. In this study, we demonstrated that MFG-E8 is enriched in undifferentiated but diminished in differentiated ESCs ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}); upregulation of MFG-E8 promotes successful engraftment of non-self ESCs and their derivatives across the MHC barrier ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [S1](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}).

Apparently, MFG-E8 is a key determinant in ESC-induced T cell suppression in a PKCθ-dependent manner. By suppressing PKCθ phosphorylation ([Figures 6](#fig6){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}), ESC-produced MFG-E8 inhibits Th1/Th2/Th17 subpopulations while increasing regulatory T cells ([Figures 4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [S1--S3](#mmc1){ref-type="supplementary-material"}). A study regarding MFG-E8-mediated tissue regeneration has shown that MFG-E8 transduced its downstream signaling for mucosal healing by activating intracellular PKCε in epithelial cells ([@bib3]). Given the premise of similar structures shared between PKCθ and PKCε ([@bib22]), our findings regarding an MFG-E8 mechanistic function on PKCθ in T cells suggest diversified modes of MFG-E8 signaling in different cell types.

Our observations that MFG-E8 did not affect *T-bet* gene expression while suppressing Th1 function (i.e., IFN-γ production) seem conflicting, which might pertain uniquely to PKCθ. Studies have illustrated that synergistic inhibition of two pathways instead of PKCθ alone is crucial for complete suppression of Th1 differentiation ([@bib15], [@bib33]). The requirement of collaborative pathways for fully controlling Th1 differentiation may provide one possible explanation regarding our *T-bet* and IFN-γ results ([@bib18], [@bib20], [@bib21]).

In summary, we elucidated an immunomodulatory mechanism by which ESCs downregulate effector T cells while upregulating Tregs via MFG-E8. Importantly, sustaining a high level of MFG-E8 expression in differentiated ESCs overcomes T cell-mediated immune rejection and facilitates transplant acceptance. This work provides insights into a potential approach for stem cell-based therapies and autoimmune diseases.

Experimental Procedures {#sec4}
=======================

Cell Lines, Animals, and Reagents {#sec4.1}
---------------------------------

Mouse ESC lines C57BL/6 (B6) and D3 (derived from 129S2/SvPas mouse blastocysts) were obtained from ATCC. Jurkat T cells were maintained in RPMI supplemented with 10% fetal bovine serum. C57BL/6 (H-2^b^) and BALB/c (H-2^d^) mice (8--12 weeks old) were purchased from Charles River Laboratories and maintained at the University of Ottawa according to the Canadian Council on Animal Care guidelines under the protocol approved by the Animal Use Subcommittee (permit BMI-2025). Recombinant mouse MFG-E8 (rmMFG-E8) was purchased from R&D Systems, and MFG-E8 antibody was prepared as described previously ([@bib13]). Other antibodies used were described below or in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for detailed procedures.

Teratoma Formation, Transplantation of EBs under Kidney Capsules, and Histological and Immunofluorescent Analyses {#sec4.2}
-----------------------------------------------------------------------------------------------------------------

B6-WT and B6-MFG-E8 ESCs were harvested, and one to three million cells were injected subcutaneously into the flank region of syngeneic C57BL/6 (n = 10) or allogeneic BALB/c (n = 18) mice to generate teratomas. Differentiated EBs were transplanted under the kidney capsules (syngeneic transplantation: n = 16; allogeneic transplantation: n = 17). Frozen tumor sections were evaluated after H&E staining or immunostaining. All of the specimens were coded so that the measurements were performed blindly for final analysis. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

Lentiviral Production, MFG-E8 Transduction, and Characterization of B6-MFG-E8 ESC {#sec4.3}
---------------------------------------------------------------------------------

293 T cells were transfected with MFG-E8 lentiviral vector encoding full-length MFG-E8 and a GFP marker (Addgene plasmid \#46847), and two packing plasmids psPAX2 and pMD2.G (Addgene plasmids 12259 and 12260) using Lipofectamine 2000 (Invitrogen). Lentivirus was harvested and concentrated using Lenti-X concentrator (Clontech) according to the manufacturer's instruction. B6 wild-type (B6-WT) ESCs were infected with lentivirus in the presence of 10 μg/ml polybrene (Sigma). Puromycin selection (2 μg/ml) started 48 hr after lentiviral transduction for 2 weeks with daily medium change. After establishing a stable cell line with upregulated MFG-E8, B6-MFG-E8 ESCs were cultured in ESC growth medium containing 1 μg/ml of puromycin. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

ESC Differentiation {#sec4.4}
-------------------

ESCs were differentiated by formation of EBs and removal of LIF. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

Preparation of ESC- and Other Cell-Derived Soluble Factors, qPCR, and Western Blot {#sec4.5}
----------------------------------------------------------------------------------

This experimental method has been described previously ([@bib24]). See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more information.

Fractionation of Mouse Splenic CD3^+^ T Cells and NK Cells {#sec4.6}
----------------------------------------------------------

Mouse spleens were removed aseptically and homogenized gently and lysed using ACK red blood cell lysis buffer (Cedarlane Laboratories, catalog no. A1049201). After two washes, splenocytes were re-suspended, and CD3^+^ T cells (\>92% purity) or NK cells (\>90% purity) were fractionated by negative selection using a magnetic labeling kit according to manufacturer instructions (STEMCELL Technologies, catalog no. 19851). See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more information.

Flow Cytometry and Intracellular Staining {#sec4.7}
-----------------------------------------

Fractionated CD3^+^ T cells were treated with different reagents as described in [Results](#sec2){ref-type="sec"}, followed by stimulation with plate-coated anti-CD3 and anti-CD28 (eBioscience, catalog no. 16-0031-85 and 16-0281-85) for 48 hr. Cells were then stained with antibodies against CD4, CD8, and surface activation markers (CD25, CD44, and CD69) (eBioscience, catalog no. 15-0041-82, 11-0081-81, 48-0253-82, 25-0691-81, and 47-0441-82, respectively). Appropriate fluorochrome-conjugated isotype matched antibodies were used as negative controls. Analysis was carried out in a Beckman Coulter Cyan cytometer, and data were analyzed using Kaluza. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for detailed procedures.

Statistical Analysis {#sec4.8}
--------------------

Results are expressed as mean ± SD. Statistical significance was determined using a Student's t test, ANOVA and Tukey HSD or chi-square test wherever applicable. Results were analyzed using R studio, and considered significant with a p value \< 0.05.
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![Undifferentiated, but Not Differentiated, ESCs Express High Levels of MFG-E8, and Upregulation of MFG-E8 Enables Survival and Engraftment of Undifferentiated and Differentiated Allogeneic ESCs\
(A) Western blot analysis of MFG-E8 protein expression in undifferentiated ESCs and their differentiated derivatives. Results are representative of three independent experiments. Densitometry results represent means ± SD of cells obtained from three separate unpooled cultures with α-tubulin as a loading control. Abbreviation: ESC B6-WT, B6 ESC line derived from C57BL/6 H-2^b^ wild-type mouse; EB, embryoid body; Day5 diff B6-WT, day5 differentiated B6-wild-type ESCs; ESC D3 cell line, D3 ESC line derived from 129S2/SvPas mouse blastocysts.\
(B) qPCR analysis of *Mfg-e*8 mRNA levels in undifferentiated B6 ESCs and their differentiated derivatives in teratomas developing 4 weeks after injection into C57BL/6 mice. Data represent means ± SD of unpooled samples from three different mice.\
(C) No detectable teratomas developed after transplantation of B6-WT ESCs into nine allogenic BALB/c mice, and five teratomas were generated after injection of B6-MFG-E8 ESCs into nine BALB/c mice (p \< 0.05). Scale bars, 0.5 cm in insets.\
(D--F) H&E staining of sections from B6-WT ESC injection sites (without teratoma formation) or B6-MFG-E8 ESC teratomas. Immunofluorescent staining of sections corresponding to each H&E staining shows expression of MHC-I (H-2K^b^, green) and infiltrations of CD4^+^ (red), CD8^+^ (red), and CD4^+^/Foxp3^+^ (red/green with image analysis results; mean ± SD from three mice per group, three sections per mouse). Nuclei were counterstained with DAPI (blue). Scale bars, 200 μm (H&E) and 20 μm (immunofluorescent staining).\
(G) Only two of eight allogeneic mice transplanted with B6-WT EBs show small implants, whereas eight of nine allogeneic mice transplanted with B6-MFG-E8 EBs are engrafted with larger implants. Arrowhead: implants. For a comparison, the same images are shown again in [Figure S1](#mmc1){ref-type="supplementary-material"}A.\
(H) Histological analysis of serial sections after 15-day transplantation of EBs differentiated from B6-WT and B6-MFG-E8 ESCs. Immunofluorescent staining of sections corresponding to each H&E staining shows expression of MHC-I (H-2K^b^, green) and infiltrations of CD4^+^ (red) and CD8^+^ (red). Nuclei were counterstained with DAPI (blue). K, kidney; scale bars, 200 μm (H&E) and 20 μm (immunofluorescent staining).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"} for CD4^+^/Foxp3^+^ Treg results. ^∗^p \< 0.05, ^∗∗^p \< *0.01*, ^∗∗∗^p \< 0.001.](gr1){#fig1}

![Teratoma Formation of B6-WT and B6-MEG-E8 ESCs in Syngeneic C57BL/6 Mice\
(A) B6 wild-type ESCs (B6-WT) were transduced with a lentiviral vector encoding MFG-E8 and GFP, followed by drug selection to establish a stable ESC line with upregulated MFG-E8 expression (B6-MFG-E8 ESCs). qPCR and western blot were performed to assess MFG-E8 expression as indicated. *β-Actin* was used as a normalization control for qPCR and α-tubulin for western blot (which was quantified by densitometry from three independent experiments).\
(B) The expression levels of MFG-E8 protein in teratomas after transplantation of B6-MFG-E8 and B6-WT ESC cells into syngeneic mice. n = 3, ^∗^p \< 0.05.\
(C) Both B6-WT and B6-MFG-E8 ESCs formed teratomas in syngeneic C57BL/6 mice after 4 weeks of transplantation into two flank regions (n = 5 mice). Scale bars, 1 cm.\
(D) Teratomas generated from both B6-WT and B6-MFG-E8 ESCs were composed of tissues representing three germ layers, including ectoderm (i, ii: neural rosettes and glial tissue; iii, iv: cystic epithelium), mesoderm (v: striated muscle; vi: cartilage and osteoid island), and endoderm (vii, viii: glandular epithelium). Scale bars, 50 μm.\
Abbreviations: Diff ESC, differentiated ESCs; Macrophage, RAW macrophage line as a positive control; Myoblast, C2C12 myoblast cells as a negative control.](gr2){#fig2}

![Immunogenicity of Tissues Derived from Undifferentiated and Differentiated B6-WT and B6-MFG-E8 ESCs in Syngeneic Recipients\
(A) Boxplot of mean fluorescent intensity of MHC-I (H-2K^b^) and MHC-II (I-A^b^) in undifferentiated and differentiated (diff) B6-WT and B6-MFG-E8 ESCs. Data represent median ± interquartile range (P25--P75) based on flow cytometric analyses using three unpooled different cell passages and cultures for each group. ^∗∗∗^p \< 0.005; ns, not significant.\
(B and C) The expression of H-2K^b^ (green), CD4 (red), and CD8 (red) in tumors generated from B6-WT and B6-MFG-E8 ESCs after implanted into syngeneic hosts (n = 5 mice in each group). Nuclei were counterstained with DAPI (blue). Scale bars, 10 μm (B), 200 μm (C, H&E), and 20 μm (C, CD4 and CD8).\
(D and E) EBs derived from B6-WT and B6-MFG-E8 ESCs were differentiated for 7 days, showing a significant decrease in pluripotency genes (qPCR). Data represent mean ± SD of at least three independent experiments.\
(F and G) The above EBs were transplanted into syngeneic mice C57BL/6 under kidney capsules and engrafted (eight out of eight for B6-WT and eight out of eight for B6-MFG-E8). Histological analysis of serial sections of syngeneic B6-WT and B6-MFG-E8 EBs 12 days after transplantation. The expression of H-2K^b^ (green) was detected. Scale bars, 100 μm, top panels (H&E); 20 μm, low panels (H-2K^b^ expression, green). Nuclei were counterstained with DAPI (blue).](gr3){#fig3}

![MFG-E8 in ESCs Suppresses T Cell Activation and Proliferation\
Negatively selected C57BL/6 CD3^+^ T cells were incubated with different treatment reagents, followed by stimulation with plate-bound anti-CD3/CD28 antibodies.\
(A) After stimulation, T cells were either untreated (stimulated) or treated with vehicle control (Ct), ESC-derived soluble factors alone (ESC-ext prepared from D3 ESCs derived from 129S2/SvPas mouse blastocysts, 0.23 mg/ml), or in combination with anti-MFG-E8 antibody (2.5 μg/ml) for 24 hr. The cells were then stained for CD4, CD8, and activation markers CD25 and CD69 and subsequently analyzed by flow cytometry.\
(B) The surface expression of CD25, CD44, and CD69 on CD4^+^ and CD8^+^ T cells was analyzed by flow cytometry in untreated control (Ct), stimulated control, recombinant mouse MFG-E8 (rmMFG-E8) alone, rmMFG-E8 with isotype antibodies (iso Ab), rmMFG-E8 with anti-MFG-E8 antibody, differentiated ESC-derived soluble factors (Diff ESC-ext from D3 ESCs), or Diff ESC-ext with rmMFG-E8. The dot plots are all from one experiment in which cells were stained for CD25 and CD69 markers, and three experiments were performed with similar results. Histograms represent the mean fluorescent intensity (MFI) of either CD4^+^ or CD8^+^ T cells with CD44 expression for each treatment group. Error bars indicate mean ± SD from three independent experiments; ^∗^p \< 0.05 (ANOVA and Tukey HSD).\
(C) Proliferation assays were performed on CFSE-labeled C57BL/6 CD3^+^ splenic lymphocytes. Results are representative of three independent experiments.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![MFG-E8 in ESCs Suppresses Th1, Th2, and Th17 Subsets while Enhancing the Treg Subpopulation\
(A) Gene expression of transcriptional factors representing Th1, Th2, and Th17 (qPCR). Purified CD3^+^ splenic T cells were primed with anti-CD3/CD28 for 3 days and then treated with either D3 ESC-derived soluble factors (D3 ESC-ext, D3 ESC line derived from 129S2/SvPas mouse blastocysts) or rmMFG-E8 in the presence of absence of MFG-E8 blocking antibody, followed by PMA stimulation. Expression levels of mRNA of transcriptional factors (*T-bet*, *Rorγt*, *Gata3*, and *Foxp3*) were determined by qPCR. Data represent mean ± SD of at least three independent experiments; ^∗^p \< 0.05.\
(B--D) rmMFG-E8 is capable of suppressing IFN-γ, IL-4, and IL-17 production. The cells were stained with fluorescent-labeled antibodies against CD4, CD25, or CD69 for surface markers and IFN-γ, IL-4, and IL-17 for intracellular cytokines, followed by flow cytometric analysis. Histograms are shown as mean ± SD of the absolute number of cells expressing each cytokine from three independent experiments (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005).\
(E) Expression of FOXP3. T cells treated and stimulated as described above were stained for CD4 and CD25 surface markers and then analyzed for intracellular FOXP3 expression by flow cytometry to assess the Treg subpopulation. The dot plots are all from one experiment, and three experiments were performed with similar results.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![MFG-E8 in ESCs Inhibits PKCθ Activation\
(A) Negatively selected C57BL/6 CD3^+^ T cells were treated with undifferentiated ESC-derived soluble factors (ESC-ext, prepared from D3 ESCs derived from 129S2/SvPas mouse blastocysts) alone or in combination with either control isotype antibody or anti-MFG-E8 antibody, and stimulated with anti-CD3/CD28 antibodies. For western blot analysis, cell lysates were probed with antibodies to phosphorylated-PKCθ (Ther538), total PKCθ, and α-tubulin (as a loading control).\
(B) Cells were treated with recombinant mouse MFG-E8 (rmMFG-E8) in the absence or presence of control isotype antibody or  anti-MFG-E8 antibody and analyzed by western blot.\
(C) Cells were treated with soluble factors derived from undifferentiated D3 ESCs (ESC-ext), differentiated D3 ESCs (Diff ESC-ext), or C2C12 myoblast cell line (C2C12 myoblast cell-ext) alone or in combination with rmMFG-E8 and then analyzed by western blot.\
(D) The αV integrin-blocking antibody (anti-αV Ab) was introduced to restrain the binding of MFG-E8 to its receptor. Cell lysates were then analyzed for levels of PKCθ phosphorylation by densitometry with α-tubulin as a loading control. Bar graphs represent mean ± SD from at least three independent experiments.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}
